image
Healthcare - Medical - Devices - NASDAQ - US
$ 28.5
-2.8 %
$ 407 M
Market Cap
-27.94
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SRDX stock under the worst case scenario is HIDDEN Compared to the current market price of 28.5 USD, Surmodics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SRDX stock under the base case scenario is HIDDEN Compared to the current market price of 28.5 USD, Surmodics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SRDX stock under the best case scenario is HIDDEN Compared to the current market price of 28.5 USD, Surmodics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SRDX

image
$42.0$42.0$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
126 M REVENUE
-4.91%
-5.64 M OPERATING INCOME
-109.61%
-11.5 M NET INCOME
-651.43%
248 K OPERATING CASH FLOW
-97.64%
-2.94 M INVESTING CASH FLOW
56.95%
-2.95 M FINANCING CASH FLOW
-16.03%
29.9 M REVENUE
-9.95%
-2.48 M OPERATING INCOME
-304.73%
-3.65 M NET INCOME
-5.86%
-7.89 M OPERATING CASH FLOW
-215.80%
3.7 M INVESTING CASH FLOW
-60.90%
-1.2 M FINANCING CASH FLOW
22.98%
Balance Sheet Surmodics, Inc.
image
Current Assets 81.3 M
Cash & Short-Term Investments 40.1 M
Receivables 23.2 M
Other Current Assets 18 M
Non-Current Assets 97.3 M
Long-Term Investments 0
PP&E 28 M
Other Non-Current Assets 69.3 M
22.46 %12.97 %10.10 %15.67 %38.80 %Total Assets$178.6m
Current Liabilities 20.5 M
Accounts Payable 0
Short-Term Debt 1.04 M
Other Current Liabilities 19.5 M
Non-Current Liabilities 39.1 M
Long-Term Debt 32.2 M
Other Non-Current Liabilities 6.92 M
32.69 %53.97 %11.60 %Total Liabilities$59.7m
EFFICIENCY
Earnings Waterfall Surmodics, Inc.
image
Revenue 126 M
Cost Of Revenue 33 M
Gross Profit 93.1 M
Operating Expenses 98.7 M
Operating Income -5.64 M
Other Expenses 5.9 M
Net Income -11.5 M
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)126m(33m)93m(99m)(6m)(6m)(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
73.81% GROSS MARGIN
73.81%
-4.48% OPERATING MARGIN
-4.48%
-9.15% NET MARGIN
-9.15%
-9.71% ROE
-9.71%
-6.46% ROA
-6.46%
-5.46% ROIC
-5.46%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Surmodics, Inc.
image
20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -11.5 M
Depreciation & Amortization 8.69 M
Capital Expenditures -3.49 M
Stock-Based Compensation 8.22 M
Change in Working Capital -5.36 M
Others 995 K
Free Cash Flow -3.24 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Surmodics, Inc.
image
Wall Street analysts predict an average 1-year price target for SRDX of $42 , with forecasts ranging from a low of $36 to a high of $46 .
SRDX Lowest Price Target Wall Street Target
36 USD 26.32%
SRDX Average Price Target Wall Street Target
42 USD 47.37%
SRDX Highest Price Target Wall Street Target
46 USD 61.40%
Price
Max Price Target
Min Price Target
Average Price Target
505045454040353530302525May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Surmodics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
276 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions. zacks.com - 2 weeks ago
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL Thrombectomy System, the latest in a suite of Pounce Thrombectomy systems that provide rapid endovascular removal of acute or chronic clot from peripheral arteries. Intended for removal of thrombi and emboli from peripheral arteries ranging from 5.5–10 mm in diameter,. businesswire.com - 2 weeks ago
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months. zacks.com - 1 month ago
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court. zacks.com - 1 month ago
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR LLC (“GTCR”), which have an equity investment in Biocoat Inc., a maker of medical coatings: “Surmodics. businesswire.com - 1 month ago
FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, with the regulatory agency alleging the deal was anticompetitive. reuters.com - 1 month ago
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 2 months ago
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch planned following completion of the LMR. businesswire.com - 2 months ago
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues. zacks.com - 2 months ago
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 2 months ago
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago. zacks.com - 2 months ago
Here's Why You Should Add Surmodics Stock to Your Portfolio Now SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months. zacks.com - 2 months ago
8. Profile Summary

Surmodics, Inc. SRDX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 407 M
Dividend Yield 0.00%
Description Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Contact 9924 West 74th Street, Eden Prairie, MN, 55344-3523 https://www.surmodics.com
IPO Date March 4, 1998
Employees 389
Officers Mr. John D. Manders Corporate Controller, Vice President of Finance & Principal Accounting Officer Ms. Teryl L. W. Sides Senior Vice President & President of Vascular Interventions Mr. Gary R. Maharaj Chief Executive Officer, President & Director Mr. Joseph J. Stich Senior Vice President of Human Resources & President of In Vitro Diagnostics Joel Suiter Director of Corporate Development Mr. Timothy J. Arens Senior Vice President of Finance & Information Technology and Chief Financial Officer Mr. Charles W. Olson Senior Vice President & President of Medical Device Coatings Mr. Gordon S. Weber J.D. Senior Vice President of Legal, General Counsel & Secretary